CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 113 enrolled
Drug / intervention
Clopidogrel 75 mg daily +1 moredrug
Likely dose
Clopidogrel 75 mg orally dailyAI-extracted
Key inclusion· 1
  • ✓Primary multi-vessel CABG with at least two saphenous vein grafts
Key exclusion· 12
  • ✕Emergency surgery
  • ✕Valve surgery
  • ✕Redo CABG
  • ✕Left ventricular ejection fraction <25%

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00228423
NCT00228423Phase 2Completed
CompareCT.gov

Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?

Ottawa Heart Institute Research Corporation·interventional·Posted Sep 28, 2005·Updated Apr 27, 2021

In Brief

A Phase 2 clinical trial evaluating Clopidogrel 75 mg daily and water pill daily for Atherosclerosis. Completed, enrolled 113 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether the combination of clopidogrel with aspirin prevents the development of blockages (atherosclerosis) in vein grafts one year after coronary artery bypass surgery (CABG) compared to aspirin alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis
CountriesCanada
CollaboratorsSanofi, Bristol-Myers Squibb

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 28, 2005
Enrollment StartMay 1, 2006
Primary CompletionJun 1, 2009
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.8 years ago

Interventions

Clopidogrel 75 mg dailydrug

Daily dose of 75 mg Clopidogrel

water pill dailydrug

Daily dose of water pill (placebo)